Jason Gardner Sells 14,000 Shares of Magenta Therapeutics Inc (NASDAQ:MGTA) Stock

Magenta Therapeutics Inc (NASDAQ:MGTA) insider Jason Gardner sold 14,000 shares of the firm’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $15.11, for a total value of $211,540.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of MGTA opened at $14.80 on Wednesday. Magenta Therapeutics Inc has a 52 week low of $5.31 and a 52 week high of $21.00. The company has a market cap of $504.41 million and a PE ratio of -4.73. The firm has a fifty day moving average price of $15.36.

Magenta Therapeutics (NASDAQ:MGTA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.11. On average, research analysts predict that Magenta Therapeutics Inc will post -2.03 EPS for the current year.



A number of brokerages have weighed in on MGTA. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Magenta Therapeutics in a report on Friday, May 10th. Goldman Sachs Group downgraded Magenta Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $17.00 to $16.00 in a report on Sunday, March 24th. They noted that the move was a valuation call. Zacks Investment Research raised Magenta Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Saturday, March 23rd. Finally, Raymond James began coverage on Magenta Therapeutics in a report on Thursday, March 14th. They issued an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Magenta Therapeutics presently has an average rating of “Buy” and a consensus price target of $19.00.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA bought a new position in Magenta Therapeutics during the 1st quarter worth $50,000. New York State Common Retirement Fund bought a new position in Magenta Therapeutics during the 4th quarter worth $27,000. Aries Wealth Management bought a new position in Magenta Therapeutics during the 1st quarter worth $198,000. Rhumbline Advisers bought a new position in Magenta Therapeutics during the 1st quarter worth $253,000. Finally, Bank of New York Mellon Corp bought a new position in Magenta Therapeutics during the 4th quarter worth $90,000. Institutional investors own 63.62% of the company’s stock.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.

Read More: What are the FAANG Stocks?

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.